网络出版日期: 2012-12-31
基金资助
上海市自然科学基金面上项目(12ZR1422200)
Roles of histone deacetylase inhibitors in treatment of diabetes mellitus
Online published: 2012-12-31
Supported by
Shanghai Science and Technology Committee Foundation, 12ZR1422200
糖尿病的发病率逐年升高,临床迫切需要更加安全、简便、有效的治疗药物。组蛋白去乙酰化酶抑制剂(HDACi)在改善胰岛β细胞功能,保护其免受炎症因子攻击,改善外周组织胰岛素抵抗,调节免疫系统而改善代谢,减缓糖尿病并发症等方面的作用日益受到重视,有望成为糖尿病甚至是妊娠期糖尿病预防和治疗的新型药物。文章就HDACi在糖尿病治疗中的作用进行综述。
关键词: 组蛋白去乙酰化酶抑制剂; 糖尿病; 胰岛素; 治疗
陈 轩, 李华萍 . 组蛋白去乙酰化酶抑制剂在糖尿病治疗中的作用[J]. 上海交通大学学报(医学版), 2012 , 32(12) : 1641 . DOI: 10.3969/j.issn.1674-8115.2012.12.025
The prevalence of diabetes mellitus is increasing year by year, and there is an imperative need for more safe, inexpensive and effective drugs for diabetes mellitus. Histone deacetylase inhibitors (HDACi) exhibit promising properties, which can promote pancreatic islet β cell function, prevent β cells from inflammatory damage, improve insulin resistance, regulate immune system balance, improve the metabolism, and positively affect diabetic complications. HDACi may become novel drugs for the prevention and treatment of diabetes mellitus, even for gestational diabetes mellitus. The roles of HDACi in the treatment of diabetes mellitus are reviewed in this paper.
Key words: histone deacetylase inhibitors; diabetes mellitus; insulin; treatment
/
〈 |
|
〉 |